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Abstract 
Objective: Clinical management of dengue relies on careful monitoring of fluid balance combined 
with judicious intravenous (IV) fluid therapy. However, in patients with significant vascular leakage 
IV fluids may aggravate serosal fluid accumulation and result in respiratory distress.  
 
Methods: Trained physicians followed suspected dengue cases prospectively at seven hospitals 
across Asia and Latin America, using a comprehensive case-report form that included daily clinical 
assessment and detailed documentation of parenteral fluid therapy. Applying Cox regression, we 
evaluated risk factors for the development of shock or respiratory distress with fluid accumulation.  
 
Results: Most confirmed-dengue patients (1524/1734, 88%) never experienced dengue shock syn-
drome (DSS). Among those with DSS, 176/210 (84%) had fluid accumulation, and in the majority, 
(83%), this was detectable clinically. Among all cases with clinically detectable fluid accumulation, 
179/447 (40%) were diagnosed with shock or respiratory distress. The risk for respiratory distress 
with fluid accumulation increased significantly as the infused volume over the preceding 24hrs in-
creased (hazard ratio 1.18 per 10 ml/kg increase; p<0.001). Longer duration of IV therapy, use of a 
fluid bolus in the preceding 24 h, female gender and poor nutrition also constituted independent risk 
factors.  
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Conclusions: Shock and respiratory distress are relatively rare manifestations of dengue, but some 
evidence of fluid accumulation is seen in around 50% of cases. IV fluids play a crucial role in man-
agement, but they must be administered with caution. Clinically and/or radiologically detectable 
fluid accumulations have potential as intermediate severity endpoints for therapeutic intervention 
trials and/or pathogenesis studies.  
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Introduction    
With no specific therapy available, effective case management of patients with dengue relies on fre-
quent monitoring and judicious use of intravenous (IV) fluids. Guidelines for fluid therapy in dengue 
patients differentiate between maintenance, rehydration, and shock resuscitation. Isotonic crystal-
loids are recommended for maintenance or rehydration, while colloid solutions are often recom-
mended alongside crystalloids for shock resuscitation (1, 2). In patients with vascular leakage, how-
ever, IV fluid therapy can aggravate fluid accumulation and lead to respiratory distress (2, 3). Clini-
cally detectable fluid accumulation is currently considered as a warning sign for severe dengue (1), 
but this association has not been formally validated. 
 
The aetiology of vascular leakage in dengue is not well understood, yet the underlying increased 
capillary permeability constitutes the main pathological mechanism implicated in severe dengue. 
Factors believed to predispose to a more severe disease course include secondary infection with a 
heterologous serotype (4-6), host genetics (7), nutritional status (8, 9), gender (10, 11), and comor-
bidities such as lung disease (12), diabetes mellitus, or arterial hypertension (13, 14).  
 
To date, use of IV fluids for dengue has not been evaluated using a standardized data collection 
instrument across multiple sites. Using the data from a large observational hospital-based study, we 
describe the presentation at first severe event for (a) shock, stratified by the presence of fluid accu-
mulation; and (b) the subsequent occurrence of respiratory distress with fluid accumulation. We also 
assess the influence of IV fluid therapy on these parameters. 
 
Methods  
Details of the prospective observational study, performed in 11 hospitals in 7 endemic countries 
across 2 continents, have been published elsewhere (15). In short, patients were recruited upon 
hospital admission, and then followed daily for a median of 4.5 days (90% range 3-7 days) using a de-
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tailed case report form (CRF) to document past medical history, clinical symptoms, examination find-
ings and management, focusing in particular on fluid therapy; the purpose and type of IV fluid given 
(maintenance only, rehydration, shock resuscitation; crystalloid, colloid, blood), and the total vol-
ume in ml/kg/24h were recorded each day. Standard operating procedures described the definitions 
for all clinical signs and symptoms and provided guidelines for completing the CRF. Data were col-
lected for 24 h-periods between daily clinical assessments scheduled at the same time each day. The 
study was conducted in accordance with GCP guidelines including WHO-trained clinical monitors. 
Dengue diagnostic testing was performed in each participating country in accordance with validated 
local protocols. According to the specific tests performed, criteria were defined for confirmed and 
highly suggestive infection, involving paired specimens for serologically confirmed dengue. Only 10% 
of the patients were classified as highly suggestive, the remaining 90% were confirmed by the diag-
nostic algorithm. Data were analysed using STATA version 12 (STATA corporation, College Station, 
Texas). Ethical clearance was obtained from the Institutional Review Board (IRB) of WHO and the re-
spective IRB of each participating institution.  
 
Definitions and endpoints  
Shock was assessed clinically, and defined as a state of reduced end-organ perfusion presenting with 
weak pulse and/or narrowing of pulse pressure, and/or hypotension for age, plus cold, clammy skin 
or increased capillary refill time, or peripheral cyanosis, or skin mottling (15).  
 
Fluid accumulation was based on clinical or radiological findings (CXR/USS). Clinical fluid accumu-
lation was defined as a clinically detectable pleural effusion or ascites noted on any of the daily as-
sessments. Radiological fluid accumulation was assessed within 24 hours of defervescence, and was 
defined as presence of a pleural effusion on CXR or a serosal fluid collection on ultrasound. CXR was 
available in the majority of the hospitals and was carried out in 88% of the patients. Respiratory dis-
tress was defined as nasal flaring, tachypnoea, or in-drawing and retractions of the chest wall. 
 
We evaluated the association of IV fluid therapy with the events of interest, adjusting for known 
confounders as for example demographics and anthropometry. The parameters assessed were IV 
fluid administration before enrolment; number of days with IV fluid therapy before the day of the 
event; volume of IV fluid (per 10 ml/kg) and whether an IV fluid bolus was given during the preced-
ing 24 h-period. As enrolment covariates we included day of illness (DOI), presence of comorbidities, 
referral status, and body mass index (BMI), using the WHO reference standards for underweight and 
overweight (Annex, Table S1) (16-18).   
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Analysis 
The spectrum of the clinical manifestations of vascular leakage was stratified into three categories to 
allow for potential heterogeneity in the risk profiles. We describe the frequency of the presentation 
at first event for (a) fluid accumulation alone, (b) shock without fluid accumulation, and (c) shock 
with fluid accumulation (Figure 1), as well as the occurrence and evolution of respiratory distress. 
 
We used Cox regression to explore associations between use of IV fluid therapy over time with 
subsequent development of shock without fluid accumulation, shock with fluid accumulation, and 
respiratory distress with fluid accumulation. Within each analysis, data were included while the per-
son was at risk for the endpoint in question; thus for patients who experienced the event of interest, 
analysis was restricted to the days before it occurred. Cases who experienced the event on the study 
enrolment day were excluded from the Cox regression analysis since detailed information about 
prior IV fluid use was not available.  
 
Patients who developed severe bleeding while at risk for any of the endpoints were excluded 
from the analysis. However, if a patient developed severe bleeding on the day of the event or subse-
quently (i.e. they had already ceased to be at risk for the endpoint), the explanatory variables were 
included from the preceding 24h time period. Apart from these exclusions for severe bleeding, pa-
tients who did not experience the relevant endpoint were considered at risk until being censored on 
illness day 10. To allow for time-dependent evolution of variables, the data were analysed at the 
level of person-day, i.e. one record for each ~24 h-period for each patient. 
 
Univariable regressions were carried out with all covariates. A full multivariable model with the 
resulting covariates of the univariable analysis (p < 0.2) was run using a stepwise backward and for-
ward selection algorithm with a significance level of 0.2 for removal/addition. Age group (<15/≥15 
years) was included in all models as an a priori confounder. Any covariates not retained by the step-
wise algorithm were again added and dropped manually one by one, and were kept in the model if 
the p-value was below 0.2.  
 
Results 
The 1501 dengue patients from Southeast Asia (SEA) and 233 from Latin America (LA) with con-
firmed dengue were included in this analysis (Table 1). The majority of the patients were children, 
due to the prevailing epidemiology in SEA and the participating hospitals; the hospital in Thailand, 
two of three hospitals in Vietnam, and the hospital in Nicaragua were paediatric facilities. Pre-
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existing comorbidities (N=147) were reported in 11.8% of the adults (age>15 years) and 6.3% of the 
children (age<15 years), mostly asthma (N=45), peptic ulcer (N=16), and arterial hypertension 
(N=14). 248 patients were referred from another inpatient facility or hospital, and 628 patients were 
referred from an outpatient facility. 8.4% of the patients (N=146) required ICU-level medical care at 
the time of enrolment.  
 
Frequency of shock and severity at time of first event 
A large majority (88%) of the 1734 hospitalized patients never experienced shock (N=1524; mean 
DOI at enrolment 4.48; 95%CI 4.43-4.54). Shock occurred in 210 patients, of whom 151 presented 
with shock at enrolment (mean DOI 4.92; 95%CI 4.78-5.06) and 59 developed shock after enrolment 
(mean DOI at enrolment 4.25; 95%CI 3.97-4.53, mean DOI at shock 5.75; 95%CI 5.45-6.05) (Figure 1).  
 
In 821 patients (47%) none of the events (shock, fluid accumulation, or respiratory distress) oc-
curred over the course of hospitalisation (mean DOI at enrolment 4.42; 95%CI 4.35-4.49), while 672 
patients (39%) experienced fluid accumulation without shock (mean DOI at enrolment 4.56, 95%CI 
4.49-4.64) and 17 patients experienced fluid accumulation and respiratory distress without shock.  
 
At the first day of shock, 102 of 210 shock cases were diagnosed with shock only (mean DOI 4.83; 
95%CI 4.66-5.01), 82 with shock plus fluid accumulation (mean DOI 4.79; 95%CI 4.58-5.01), and 22 
with shock plus fluid accumulation and concurrent respiratory distress (mean DOI 4.23; 95%CI 3.82-
4.64) (Figure 1).  
 
Disease progression under prospective follow-up 
Among the 672 patients with documented fluid accumulation who were never diagnosed with shock, 
15 subsequently developed respiratory distress (2.2%). In total, respiratory distress with fluid accu-
mulation was diagnosed in 32/1524 (2.2%) cases who never developed shock.  
 
Among the DSS cases without fluid accumulation at the onset of shock (N=102), 70 developed 
fluid accumulation subsequently and 12 (12%) proceeded to respiratory distress with fluid accumula-
tion, either concurrently or sequentially.  
In addition, 8 of 82 DSS patients (10%) with fluid accumulation at initial presentation proceeded 
to develop respiratory distress. Altogether, respiratory distress was diagnosed in 49 cases with 
shock, including 22 cases of concurrent shock and respiratory distress with fluid accumulation, and 
22 cases where respiratory distress developed after shock (Figure 1).  
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Detection of fluid accumulation 
Fluid accumulation was documented in 868/1734 (50.1%) of all patients. Among the patients with 
fluid accumulation who never proceeded to shock or respiratory distress (N=657), 59% (389) were 
diagnosed by radiological methods only, while 41% had evidence of clinical fluid accumulation (clini-
cal pleural effusion or ascites). In contrast, all 32 patients who were never diagnosed with shock, but 
developed respiratory distress with fluid accumulation, had clinically detectable fluid accumulation. 
Among the patients with shock, 177/210 (84%) had fluid accumulation and in 147 of these cases 
(83%) this was detectable clinically.  
 
When we compared radiological versus clinical detection of fluid accumulation on 129 days with 
shock (110 patients) and 76 days with respiratory distress (60 patients) we saw high agreement rates 
(Table 2). In shock cases, clinical signs of fluid accumulation were recorded on 71/97 days with ra-
diologically confirmed evidence of fluid accumulation (73.2%). In 16 cases, clinical signs of fluid ac-
cumulation were recorded which could not be verified by CXR or US. This mismatch was caused by 
absence of pleural effusion by CXR in 8 cases, absence of pleural effusion by ultrasound in 3 cases, 
and absence of ascites by ultrasound in 1 case. In another 3 cases, ascites was diagnosed clinically, 
but abdominal ultrasound was not performed and pleural effusion was absent on CXR.  
 
For respiratory distress, clinical clinical signs of fluid accumulation were recorded on 64/68 days 
with radiological confirmed evidence of fluid accumulation (94%). A clinical pleural effusion was di-
agnosed which was not visible on CXR in three cases, and by ultrasound in one case. 
 
Impact of IV fluid therapy 
Overall, 943 patients (54.4%) received IV fluids during the prospective follow-up period. IV fluids 
were given on 3072 patient-days, representing 38.8% of the total patient-days under observation. 
211 patients had already received IV fluid therapy before enrolment while being managed at an-
other facility. The median number of days with IV fluids per patient was three (IQR 2-4). In 810 pa-
tients, IV fluids were administered on consecutive days (mean number of days 3.1; IQR 2-4 days).  
The median volume of IV fluid given for maintenance was 50.0 ml/kg per day (IQR: 29.8-71.6), for 
rehydration 50.0 ml/kg (IQR: 33.6-71.4), and for shock resuscitation 64.7 ml/kg (IQR: 39.1-89.3). As 
the total amount per 24 hours was recorded, these estimates are averages and may include times 
without any IV fluid. In the case of shock resuscitation, the total amount over 24h included a bolus of 
IV fluid. 
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To evaluate the impact of IV fluid therapy we selected the subset of patients in whom complica-
tions developed during the prospective follow-up period. Univariable regressions were first carried 
out separately for shock without fluid accumulation and shock with fluid accumulation, and subse-
quently combined as the profile of risk factors proved to be comparable (Annex, Table S2). In the 
univariable regressions, shock (combined) was significantly associated with age below 15 years (HR 
2.09; p=0.020), underweight (HR 2.42; p=0.007), IV fluid administration before enrolment (HR 2.52; 
p=0.010), and increasing volume of IV fluid (per 10 ml/kg) in the preceding 24 h (HR 1.10; p=0.022) 
(Table 3). Respiratory distress with fluid accumulation was associated with age younger than 15 
years (HR 4.38; p<0.001), referral from another inpatient facility (HR 2.88; p<0.001), and duration of 
IV fluid therapy (HR 1.99; p<0.001), amount of IV fluids in the preceding 24h (HR 1.33; p<0.001), as 
well as receipt of an IV fluid bolus in the preceding 24 h (HR 10.71; p<0.001) (Table 3).  
 
Multivariable regressions were adjusted for age group and otherwise restricted to the most influ-
ential covariates with p<0.2 (Table 4). The risk for shock was significantly increased in females (ad-
justed hazard ratio [AHR] 2.05; p=0.031), in underweight patients (AHR 2.62; p=0.012) and in the 
cases that had received IV fluids before enrolment (AHR 2.60; p=0.033), adjusted for age group, and 
amount of IV fluid in the preceding 24 h (AHR 1.11; p=0.059). The risk for respiratory distress with 
fluid accumulation was increased in the age group <15 years (AHR 3.85; p=0.001), and with longer 
duration and greater volumes of IV fluid therapy. Longer duration of IV fluid therapy (AHR 1.66 per 
additional day; p=0.004), greater amounts of IV fluid therapy during the preceding 24 h (AHR 1.18 
per 10 ml/kg; p<0.001), and IV fluid bolus administered in the preceding 24 h (AHR 2.90; p=0.005) 
each were independent risk factors for respiratory distress with fluid accumulation. 
 
Discussion  
A large proportion, 88%, of the 1734 hospitalized dengue patients in this prospective multicentre 
study never experienced shock, although in some cases pre-hospital treatment may have prevented 
complications. In contrast, fluid accumulation was documented in approximately half of the 1734 
cases. The agreement between clinically and radiologically detected fluid accumulation was high, 
particularly when complications were present. However, minor fluid accumulation might not have 
been detected in some cases, especially in the absence of other clinical features suggesting vascular 
leakage. Not surprisingly, the proportion of cases with documented fluid accumulation was signifi-
cantly larger among shock cases (84%; 95%CI 79-89%) than patients who never experienced shock 
(45%; 95%CI 43-48%). If present, fluid accumulation was detected by clinical assessment in 41% of 
the 657 cases who never progressed to shock or respiratory distress versus 83% of the 210 shock 
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cases. In all patients who never had shock, but were diagnosed with respiratory distress, fluid accu-
mulation was detected in by clinical assessment.  
 
Among all cases with clinical fluid accumulation identified at some point during the prospective 
evaluation, 179/447 (40%) also developed shock or respiratory distress. Thus, across the spectrum of 
vascular leakage manifestations, clinical fluid accumulation was associated with more severe dis-
ease.   
Vascular leakage is the defining feature of severe dengue and is primarily responsible for in-
travascular volume depletion and shock, although the volume loss may be compounded by sweating, 
vomiting, diarrhoea, and reduced fluid intake. Respiratory distress is usually a late phenomenon, due 
to fluid accumulation in the pleural or peritoneal cavity, or occasionally to pulmonary edema in se-
vere cases. However, clinical or radiological detection of fluid accumulation earlier in the illness 
course can be a useful indicator to assess the degree of underlying vascular leakage. Leakage sever-
ity is often quantified by measuring the degree of haemoconcentration, with a haematocrit change 
of greater than 20% typically used as an absolute cut-off to define presence of leakage in dengue 
(19), or with additional sub-stratification to assess severity (20). However, the utility of these meth-
ods is limited by the fact that an individual’s baseline haematocrit is rarely known, and that par-
enteral fluid therapy may obscure significant changes. In several small focused studies fluid accumu-
lation documented by ultrasound has been shown to correlate with disease severity (21-24) and to 
be more sensitive at detecting vascular leakage than haematocrit changes (25), although the lack of 
defined normal ranges for the parameters of interest and the lack of specificity of the findings have 
been highlighted as potential issues (26).  
 
Our data confirm, in a much larger unselected population, that fluid accumulation is one of the 
key manifestations of dengue-induced vascular leakage, and support development of a systematic 
approach to detection, ideally to be used alongside systematic methods to identify haemoconcen-
tration in suspected cases. The association we demonstrate between detection of fluid accumulation 
and development of severe disease also provides evidence for consideration of this phenomenon as 
a potential outcome measure for dengue research, whether identified by direct examination or 
quantified radiologically in more sophisticated settings. This is of particular interest as severe dengue 
remains a relatively rare event (27, 28). 
 
These findings also highlight the conundrum surrounding the influence of IV fluid therapy on 
markers of vascular leakage. While fluid therapy is clearly crucial for management in many patients, 
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our results confirm the important role of parenteral fluid use in the evolution of respiratory distress 
in dengue cases with vascular leakage. We also observed an increased risk for shock in participants 
who had received IV fluids prior to enrolment, but whether the volume administered was adequate 
given the severity of leakage present before enrolment cannot be determined from these data. Of 
note however, most of the patients were previously healthy children, in whom even large volumes 
of parenteral fluid are usually rapidly excreted in normal circumstances; in such cases any degree of 
fluid accumulation indicates that abnormal permeability is present. Overload can undoubtedly be 
exacerbated by inappropriate fluid management, especially in the elderly or in individuals with un-
derlying conditions that affect cardiovascular homeostasis. To capture the full impact of interactions 
between vascular leakage and fluid management, future studies will need to be very detailed, and to 
include repeated daily assessments, to correlate the amount of fluid given with the immediate im-
pact on the medical condition of the patient.  
 
In addition to the volume and duration of parenteral fluid therapy received, we identified several 
factors – age, undernutrition, and female sex – that were associated with poor outcome in the re-
gression analyses. In line with many studies that have demonstrated a greater risk for vascular leak-
age and development of DSS among children than adults (10, 29, 30), in this study children (i.e. sub-
jects <15 years) were 3.9 times as likely as adults to proceed to respiratory distress with fluid accu-
mulation. Similarly, female patients are generally considered to have a higher risk of developing DSS 
and of dying from this complication than male patients; this could be related to health seeking be-
haviour since girls may be brought to hospital later and with more advanced disease (10). However, 
there has been more debate regarding the influence of nutritional status, with both under and over-
nutrition implicated in previous studies (31-34).  
In conclusion, in this large prospective study of hospitalized confirmed-dengue patients in which 
a uniform data-collection instrument was applied at multiple sites across 7 countries in Southeast 
Asia and Latin America, we found that although the majority of patients did not experience severe 
dengue due to vascular leakage (either manifesting as shock or respiratory distress), evidence of 
fluid accumulation was documented in 50.1% of cases (868/1734), and 40% of patients (179/447) 
with clinically detected fluid accumulation were diagnosed with shock or respiratory distress. Fluid 
therapy was associated with a greater risk of developing respiratory distress. This relationship may 
partly reflect the severity of the underlying disease process. Evidence of fluid accumulation alone 
could potentially serve as an intermediate severity endpoint for dengue research studies, although 
further work is needed to develop clear definitions and detection thresholds for clinical and radio-
logical fluid accumulation.  
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Figure Legend 
Figure 1. Manifestations of vascular leakage leading to fluid accumulation (FA) only, shock 
with/without FA, and respiratory distress (RD) with FA in 1734 dengue patients. 
1       In 3 patients the information for FA was not available.  
2 In 11 patients RD was the first event. FA was subsequently documented in 2 of those patients af-
ter RD was no longer present. 
3 In 1 patient RD only occurred before shock. In 1 patient FA only occurred before shock.  
4 In 2 patients RD occurred after shock. 
5 In 4 patients RD occurred on the same day as shock. Out of these 2 patients developed FA. 
 
 
 
   Table 1. Characteristics of 1734 study subjects at enrolment by continent 
 Asia Latin America 
N % N % 
Age:  
- 0-14 
- 15-44 
- 45+ 
 
897 
587 
17 
 
60 
39 
1 
 
165 
58 
10 
 
71 
25 
4 
Sex: 
- Male 
- Female 
 
797 
704 
 
53 
47 
 
127 
106 
 
55 
45 
BMI* 
- Underweight 
- Normal 
- Overweight 
 
510  
682  
289  
 
34 
45 
19 
 
41 
114 
69 
 
18 
49 
30 
DOI at time of enrolment 
- ≤3 
- >3 
 
202 
1,299 
 
13.5 
86.5 
 
74 
159 
 
31.8 
68.2 
History of comorbidity  
102 
 
6.8 
 
45 
 
19.3 
Referral 
- from outpatient facility 
- from inpatient facility 
 
564 
223 
 
37.6 
14.9 
 
64 
25 
 
27.5 
10.7 
Medical protocol at enrolment 
- Standard 
- Intermediate 
 
774 
597 
 
51.6 
39.8 
 
135 
82 
 
57.9 
35.2 
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- ICU-level  130 8.7 16 6.9 
 
Total 
 
1501 
  
233 
 
 
* BMI categories: underweight in patients ≥19 years: BMI <18.5; overweight in patients ≥ 19 years: 
BMI >=25; underweight in patients <19 years: BMI < -1 SD according to WHO reference standard; 
overweight in patients <19 years: BMI >= 1 SD according to WHO reference standard. 
 
 
 
  
Table 2. Comparison of radiological assessment of fluid accumulation (ultrasound or CXR) with clini-
cal assessment on 129 days with shock (110 patients) and 76 days with respiratory distress (60 pa-
tients)   
 
 
Shock Clinical signs of FA  
- + Total  
Radiological evi-
dence of FA  
 
- 16 16 32 
+ 26 71 97 
Total  42 87 129 
 
Respiratory distress Clinical signs of FA  
- + Total  
Radiological evi-
dence of FA  
 
- 8 4 12 
+ 0 64 64 
Total  8 68 76 
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Table 3. Univariable Cox regression on risk factors for subsequent shock and respiratory distress with fluid accumulation (RD+FA). The subset of patients in 
the regression analysis includes those with event of interest developing during the prospective follow-up period and the patients where no event occurred 
(and follow-up information was available). 
 
 No shock or RD 
N = 1478 
Shock 
N = 56 
RD+FA 
N = 54 
Demographics / anthropometry / referral history / past medical history  
 N (%) N (%) HR (p-value) 95%CI N (%) HR (p-value) 95%CI 
Age group  
< 15 years 
>= 15 years 
 
885 (59.9) 
593 (40.1) 
 
43 (76.8) 
13 (23.2) 
 
reference 
2.09 (0.020) 
 
 
1.13-3.89 
 
47 (87.0) 
7 (13.0) 
 
reference 
4.38 (<0.001) 
 
 
1.97-9.70 
Sex 
male 
female 
 
802 (54.3) 
676 (45.7) 
 
25 (44.6) 
31 (55.4) 
 
reference 
1.50 (0.133) 
 
 
0.88-2.54 
 
25 (46.3) 
29 (53.7) 
 
reference 
1.36 (0.258) 
 
 
0.80-2.33 
BMI 
underweight  
normal 
overweight 
missing values 
 
456 (30.9) 
692 (46.8) 
309 (20.9) 
21 (1.4) 
 
25 (44.6) 
15 (26.8) 
12 (21.4) 
4 (7.1) 
 
2.42 (0.007) 
reference 
1.82 (0.121) 
 
1.28-4.59 
 
0.85-3.90 
 
18 (33.3) 
20 (37.0) 
13 (24.1) 
3 (5.6) 
 
1.26 (0.474) 
reference 
1.51 (0.244) 
 
0.67-2.39 
 
0.75-3.04 
Continent 
SE Asia 
L America 
 
1279 (86.5) 
199 (13.5) 
 
46 (82.1) 
10 (17.9) 
 
reference 
1.22 (0.577) 
 
 
0.61-2.45 
 
49 (90.7) 
5 (9.3) 
 
reference 
0.65 (0.365) 
 
 
0.26-1.65 
DOI at time of enrolment 
<=3  
> 3 
 
251 (17.0) 
1227 (83.0) 
 
13 (23.2) 
43 (76.8) 
 
reference 
1.94 (0.134) 
 
 
0.82-4.64 
 
8 (14.8) 
46 (85.2) 
 
reference 
2.38 (0.101) 
 
 
0.84-6.68 
Outpatient referral 
not referred 
referred 
missing values 
 
940 (63.6) 
535 (36.2) 
3 (0.2) 
 
33 (58.9) 
23 (41.1) 
- 
 
reference 
1.39 (0.231) 
 
 
0.81-2.37 
 
38 (70.4) 
15 (27.8) 
1 (1.9) 
 
reference 
0.74 (0.315) 
 
 
0.40-1.34 
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Inpatient referral 
not referred 
referred 
missing values 
 
1291 (87.3) 
186 (12.6) 
1 (0.1) 
 
50 (89.3) 
6 (10.7) 
- 
 
reference 
0.85 (0.700) 
 
 
0.36-1.98 
 
37 (68.5) 
17 (31.5) 
- 
 
reference 
2.88 (<0.001) 
 
 
1.62-5.12 
Any past medical history 
not present 
present 
missing values 
 
1291 (87.3) 
115 (7.8) 
72 (4.9) 
 
44 (78.6) 
6 (10.7) 
6 (10.7) 
 
reference 
1.46 (0.381) 
 
 
0.62-3.44 
 
44 (81.5) 
6 (11.1) 
4 (7.4) 
 
reference 
1.44 (0.399) 
 
 
0.61-3.39 
 
IV fluid management  
 N (%) N (%) or mean 
(95% CI) 
HR (p-value) 95%CI N (%) or mean 
(95% CI) 
HR (p-value) 95%CI 
Fluid administration prior to en-
rolment/ referral 
no fluid 
fluid administered 
missing values 
 
 
879 (59.5) 
136 (9.2) 
463 (31.3) 
 
 
34 (60.7) 
10 (17.9) 
12 (21.4) 
 
 
reference 
2.52 (0.010) 
 
 
 
1.24-5.11 
 
 
31 (57.4) 
11 (20.4) 
12 (22.2) 
 
 
reference 
2.16 (0.029) 
 
 
 
1.08-4.31 
Amount of IV fluids (per 10 ml 
per kg) in previous 24h  
 2.38  
(1.51-3.25) 
 
1.10 (0.022) 
 
1.01-1.19 
6.56 
(5.43-7.70) 
 
1.33 (<0.001) 
 
1.25-1.40 
Number of days with IV fluid 
therapy (until previous day) 
 0.7  
(0.5-0.9) 
 
1.17 (0.279) 
 
0.88-1.56 
1.6  
(1.3-1.9) 
 
1.99 (<0.001) 
 
1.57-2.52 
IV fluid bolus in previous 24h* 
no bolus 
bolus 
missing values 
  
54 (96.4) 
1 (1.8) 
1 (1.8) 
   
37 (68.5) 
17 (31.5) 
- 
 
reference 
10.71 (<0.001) 
 
 
5.95-19.27 
 
* only evaluated for respiratory distress with fluid accumulation as endpoint 
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Table 4. Multivariable cox regression on risk factors for subsequent shock (N=40) and respiratory distress with fluid accumulation (N=52) (Patients with se-
vere bleeding while under risk for shock were excluded from the analysis as well as the patients with the outcome on first hospital visit.) 
 
 
Predictor 
 
Shock  
 
Respiratory distress with fluid accumulation 
AHR (p-value) 95%CI AHR (p-value) 95%CI 
 
Demographics / anthropometry / referral history 
Age group  
>= 15 years 
< 15 years 
 
reference 
1.92 (0.106) 
 
 
0.87-4.25 
 
reference 
3.85 (0.001) 
 
 
1.69-8.77 
Sex 
male 
female 
 
reference 
2.05 (0.031) 
 
 
1.07-3.95 
  
BMI 
underweight 
normal 
overweight 
 
2.62 (0.012) 
reference 
1.94 (0.145) 
 
1.24-5.54 
 
0.80-4.70 
  
Inpatient referral 
no  
yes 
 
 
 
  
reference 
1.81 (0.064) 
 
 
0.97-3.39 
 
IV fluid management 
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Fluid administration prior 
to enrolment/ referral 
no fluid 
fluid administered 
 
 
reference 
2.60 (0.033) 
 
 
 
1.08-6.27 
  
Amount of IV fluids (10 
ml per kg) in previous 24 
hour period 
 
1.11 (0.059) 
 
1.00-1.23 
 
1.18 (<0.001) 
 
1.10-1.28 
Number of days with IV 
fluid therapy (until previ-
ous day) 
   
1.66 (0.004) 
 
1.17-2.34 
Fluid bolus administered 
in previous 24 hour pe-
riod 
no  
yes 
   
 
reference 
2.90 (0.005) 
 
 
 
1.37-6.12 
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